Clinical Trial: Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies

U.S., May 21 -- ClinicalTrials.gov registry received information related to the study (NCT06980116) titled 'Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies' on May 12.

Brief Summary: The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of EXS73565 administered orally as a single agent in participants with relapsed/refractory B-cell malignancies.

Study Start Date: March 31

Study Type: INTERVENTIONAL

Condition: Relapsed or Refractory B-cell Malignancies

Intervention: DRUG: EXS73565

EXS73565 oral administration

Recruitment Status: RECRUITING

Sponsor: Exscientia AI Limited

Published by HT Digital...